Eli Lilly's Weight Loss Empire Just Crushed Earnings - This Bull Run Has Legs

Signal: BUY | Score: 69.6/100

LLY just delivered a jaw-dropping Q4 earnings beat that sent shares soaring, and the party's far from over. With GLP-1 drugs Mounjaro and Zepbound posting triple-digit growth and management guiding for another 25% revenue surge in 2026, this pharma giant is riding the obesity treatment wave like no other.

The Setup

The technical picture looks solid with momentum building across multiple timeframes. Our composite technical score of 68.96 reflects strong underlying price action, while the momentum score of 67.5 indicates this uptrend still has gas in the tank. More importantly, sentiment is running hot at 77.31 - when everyone's talking about your weight loss drugs, that's usually a good sign for the stock price.

The Catalyst

February 4th changed everything for LLY bulls. The company absolutely crushed Q4 2025 numbers, posting revenue of $19.3 billion (up 43% year-over-year) against consensus estimates of just $17.87 billion. The real fireworks came from their GLP-1 franchise - Mounjaro revenue exploded 110% higher while Zepbound jumped 123%.

But here's the kicker: management isn't slowing down. They guided 2026 revenue to $80-83 billion, representing 25% growth at the midpoint and well above the Street's $77.5 billion estimate. Non-GAAP EPS guidance of $33.50-35.00 implies over 40% growth. When a company this size is projecting that kind of acceleration, you pay attention.

Bull Case

• GLP-1 dominance continues: With obesity affecting 40% of U.S. adults and global demand exploding, LLY's early-mover advantage in this $100+ billion addressable market is paying massive dividends • Earnings momentum accelerating: 42% EPS growth in Q4 with 40%+ projected for 2026 - this isn't a one-quarter wonder • Pipeline diversification: Recent M&A moves into oncology and neuroscience provide growth optionality beyond GLP-1s

Bear Case

• Valuation concerns: Trading at premium multiples with high expectations baked in - any execution hiccup could trigger selling • Competition heating up: Novo Nordisk and emerging players are gunning for LLY's GLP-1 market share with competitive pricing

The Trade

Entry: Market open (current levels)
Target: 15-20% upside based on earnings momentum
Stop Loss: 8-10% below entry
Risk/Reward: 2:1
Timeframe: 3-6 months

The obesity drug revolution is real, and LLY is leading the charge. With earnings like these and guidance that aggressive, this stock deserves a spot in growth portfolios.

*This is one person's analysis, not financial advice. Always do your own research.*